Download PDF
Horm Metab Res 2014; 46(03): 193-200
DOI: 10.1055/s-0034-1367031
Endocrine Research
© Georg Thieme Verlag KG Stuttgart · New York

Testosterone Regulates Bone Response to Inflammation

J. P. Steffens
1   Department of Physiology and Pathology, School of Dentistry at Araraquara – UNESP, São Paulo State University, ­Araraquara, SP, Brazil
2   Department of Applied Oral Sciences, Center for Periodontology, The Forsyth Institute, Cambridge, MA, USA
,
B. S. Herrera
2   Department of Applied Oral Sciences, Center for Periodontology, The Forsyth Institute, Cambridge, MA, USA
,
L. S. Coimbra
1   Department of Physiology and Pathology, School of Dentistry at Araraquara – UNESP, São Paulo State University, ­Araraquara, SP, Brazil
,
D. N. Stephens
2   Department of Applied Oral Sciences, Center for Periodontology, The Forsyth Institute, Cambridge, MA, USA
,
C. Rossa Jr
1   Department of Physiology and Pathology, School of Dentistry at Araraquara – UNESP, São Paulo State University, ­Araraquara, SP, Brazil
,
L. C. Spolidorio
1   Department of Physiology and Pathology, School of Dentistry at Araraquara – UNESP, São Paulo State University, ­Araraquara, SP, Brazil
,
A. Kantarci
2   Department of Applied Oral Sciences, Center for Periodontology, The Forsyth Institute, Cambridge, MA, USA
,
T. E. Van Dyke
2   Department of Applied Oral Sciences, Center for Periodontology, The Forsyth Institute, Cambridge, MA, USA
› Author Affiliations
Further Information

Publication History

received 10 July 2013

accepted 06 January 2014

Publication Date:
13 February 2014 (online)

Also available at
    Permissions and Reprints

Abstract

This study evaluated the alveolar bone response to testosterone and the impact of Resolvin D2 (RvD2) on testosterone-induced osteoblast function. For the in vivo characterization, 60 male adult rats were used. Treatments established sub-physiologic (L), normal (N), or supra-physiologic (H) concentrations of testosterone. Forty rats were subjected to orchiectomy; 20 rats received periodical testosterone injections while 20 rats received testicular sham-operation. Four weeks after the surgeries, 10 rats in each group received a subgingival ligature around the lower first molars to induce experimental periodontal inflammation and bone loss. In parallel, osteoblasts were differentiated from neonatal mice calvariae and treated with various doses of testosterone for 48 h. Cell lysates and conditioned media were used for the determination of alkaline phosphatase, osteocalcin, RANKL, and osteoprotegerin. Micro-computed tomography linear analysis demonstrated that bone loss was significantly increased for both L and H groups compared to animals with normal levels of testosterone. Gingival IL-1β expression was increased in the L group (p<0.05). Ten nM testosterone significantly decreased osteocalcin, RANKL, and OPG levels in osteoblasts; 100 nM significantly increased the RANKL:OPG ratio. RvD2 partially reversed the impact of 10 nM testosterone on osteocalcin, RANKL, and OPG. These findings suggest that both L and H testosterone levels increase inflammatory bone loss in male rats. While low testosterone predominantly increases the inflammatory response, high testosterone promotes a higher osteoblast-derived RANKL:OPG ratio. The proresolving mediator RvD2 ameliorates testosterone-derived downregulation of osteocalcin, RANKL, and OPG in primary murine osteoblasts suggesting a direct role of inflammation in osteoblast function.

Key words

testosterone - osteoblasts - docosahexaenoic acids - RANK ligand - osteocalcin - osteoprotegerin
 

  • References

  • 1 Clarke BL, Khosla S. Androgens and bone. Steroids 2009; 74: 296-305
    CrossrefPubMedGoogle Scholar
  • 2 Vodo S, Bechi N, Petroni A, Muscoli C, Aloisi AM. Testosterone-induced effects on lipids and inflammation. Mediat Inflam 2013; 2013: 183041
    PubMedGoogle Scholar
  • 3 Gilliver SC. Sex steroids as inflammatory regulators. J Steroid Biochem Mol Biol 2010; 120: 105-115
    CrossrefPubMedGoogle Scholar
  • 4 Bain J. Testosterone and the aging male: to treat or not to treat?. Maturitas 2010; 66: 16-22
    CrossrefPubMedGoogle Scholar
  • 5 Del Fabbro E, Hui D, Nooruddin ZI, Dalal S, Dev R, Freer G, Roberts L, Palmer JL, Bruera E. Associations among hypogonadism, C-reactive protein, symptom burden, and survival in male cancer patients with cachexia: a preliminary report. J Pain Symptom Manage 2010; 39: 1016-1024
    CrossrefPubMedGoogle Scholar
  • 6 Laughlin GA, Barrett-Connor E, Bergstrom J. Low serum testosterone and mortality in older men. J Clin Endocrinol Metab 2008; 93: 68-75
    CrossrefPubMedGoogle Scholar
  • 7 Stellato RK, Feldman HA, Hamdy O, Horton ES, McKinlay JB. Testosterone, sex hormone-binding globulin, and the development of type 2 diabetes in middle-aged men: prospective results from the Massachusetts male aging study. Diabetes Care 2000; 23: 490-494
    CrossrefPubMedGoogle Scholar
  • 8 Selvin E, Feinleib M, Zhang L, Rohrmann S, Rifai N, Nelson WG, Dobs A, Basaria S, Golden SH, Platz EA. Androgens and diabetes in men: results from the Third National Health and Nutrition Examination Survey (NHANES III). Diabetes Care 2007; 30: 234-238
    CrossrefPubMedGoogle Scholar
  • 9 Laaksonen DE, Niskanen L, Punnonen K, Nyyssonen K, Tuomainen TP, Valkonen VP, Salonen R, Salonen JT. Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care 2004; 27: 1036-1041
    CrossrefPubMedGoogle Scholar
  • 10 Mellstrom D, Johnell O, Ljunggren O, Eriksson AL, Lorentzon M, Mallmin H, Holmberg A, Redlund-Johnell I, Orwoll E, Ohlsson C. Free testosterone is an independent predictor of BMD and prevalent fractures in elderly men: MrOS Sweden. J Bone Miner Res 2006; 21: 529-535
    CrossrefPubMedGoogle Scholar
  • 11 Meier C, Nguyen TV, Handelsman DJ, Schindler C, Kushnir MM, Rockwood AL, Meikle AW, Center JR, Eisman JA, Seibel MJ. Endogenous sex hormones and incident fracture risk in older men: the Dubbo Osteoporosis Epidemiology Study. Arch Intern Med 2008; 168: 47-54
    CrossrefPubMedGoogle Scholar
  • 12 Maggio M, Basaria S. Welcoming low testosterone as a cardiovascular risk factor. Int J Impot Res 2009; 21: 261-264
    CrossrefPubMedGoogle Scholar
  • 13 Traish AM, Guay A, Feeley R, Saad F. The dark side of testosterone deficiency: I. Metabolic syndrome and erectile dysfunction. J Androl 2009; 30: 10-22
    PubMedGoogle Scholar
  • 14 Traish AM, Saad F, Guay A. The dark side of testosterone deficiency: II. Type 2 diabetes and insulin resistance. J Androl. 2009. 30. 23-32
    Google Scholar
  • 15 Traish AM, Saad F, Feeley RJ, Guay A. The dark side of testosterone deficiency: III. Cardiovascular disease. J Androl 2009; 30: 477-494
    CrossrefPubMedGoogle Scholar
  • 16 Achar S, Rostamian A, Narayan SM. Cardiac and metabolic effects of anabolic-androgenic steroid abuse on lipids, blood pressure, left ventricular dimensions, and rhythm. Am J Cardiol 2010; 106: 893-901
    CrossrefPubMedGoogle Scholar
  • 17 Kanayama G, Hudson JI, Pope Jr HG. Long-term psychiatric and medical consequences of anabolic-androgenic steroid abuse: a looming public health concern?. Drug Alcohol Depend 2008; 98: 1-12
    CrossrefPubMedGoogle Scholar
  • 18 Michael H, Harkonen PL, Vaananen HK, Hentunen TA. Estrogen and testosterone use different cellular pathways to inhibit osteoclastogenesis and bone resorption. J Bone Miner Res 2005; 20: 2224-2232
    CrossrefPubMedGoogle Scholar
  • 19 Pederson L, Kremer M, Judd J, Pascoe D, Spelsberg TC, Riggs BL, Oursler MJ. Androgens regulate bone resorption activity of isolated osteoclasts in vitro. Proc Natl Acad Sci USA 1999; 96: 505-510
    CrossrefPubMedGoogle Scholar
  • 20 Huber DM, Bendixen AC, Pathrose P, Srivastava S, Dienger KM, Shevde NK, Pike JW. Androgens suppress osteoclast formation induced by RANKL and macrophage-colony stimulating factor. Endocrinology 2001; 142: 3800-3808
    CrossrefPubMedGoogle Scholar
  • 21 Vanderschueren D, Vandenput L, Boonen S, Lindberg MK, Bouillon R, Ohlsson C. Androgens and bone. Endocr Rev 2004; 25: 389-425
    CrossrefPubMedGoogle Scholar
  • 22 Hofbauer LC, Hicok KC, Chen D, Khosla S. Regulation of osteoprotegerin production by androgens and anti-androgens in human osteoblastic lineage cells. Eur J Endocrinol 2002; 147: 269-273
    CrossrefPubMedGoogle Scholar
  • 23 Chen Q, Kaji H, Kanatani M, Sugimoto T, Chihara K. Testosterone increases osteoprotegerin mRNA expression in mouse osteoblast cells. Horm Metab Res 2004; 36: 674-678
    Article in Thieme ConnectPubMedGoogle Scholar
  • 24 Ashcroft GS, Mills SJ. Androgen receptor-mediated inhibition of cutaneous wound healing. J Clin Investig 2002; 110: 615-624
    CrossrefPubMedGoogle Scholar
  • 25 Gilliver SC, Ashworth JJ, Mills SJ, Hardman MJ, Ashcroft GS. Androgens modulate the inflammatory response during acute wound healing. J Cell Sci 2006; 119: 722-732
    CrossrefPubMedGoogle Scholar
  • 26 Serhan CN. A search for endogenous mechanisms of anti-inflammation uncovers novel chemical mediators: missing links to resolution. Histochem Cell Biol 2004; 122: 305-321
    CrossrefPubMedGoogle Scholar
  • 27 Serhan CN. Resolution phase of inflammation: novel endogenous anti-inflammatory and proresolving lipid mediators and pathways. Annu Rev Immunol 2007; 25: 101-137
    CrossrefPubMedGoogle Scholar
  • 28 Spite M, Norling LV, Summers L, Yang R, Cooper D, Petasis NA, Flower RJ, Perretti M, Serhan CN. Resolvin D2 is a potent regulator of leukocytes and controls microbial sepsis. Nature 2009; 461: 1287-1291
    CrossrefPubMedGoogle Scholar
  • 29 Amano A. Host-parasite interactions in periodontitis: microbial pathogenicity and innate immunity. Periodontology 2000 2010; 54: 9-14
    CrossrefPubMedGoogle Scholar
  • 30 Eke PI, Dye BA, Wei L, Thornton-Evans GO, Genco RJ, Cdc Periodontal Disease Surveillance Workgroup . James Beck GDRP. Prevalence of periodontitis in adults in the United States: 2009 and 2010. J Dental Res 2012; 91: 914-920
    CrossrefPubMedGoogle Scholar
  • 31 Borst SE, Conover CF. Orchiectomized Fischer 344 male rat models body composition in hypogonadal state. Life Sci 2006; 79: 411-415
    CrossrefPubMedGoogle Scholar
  • 32 Haggstrom S, Lissbrant IF, Bergh A, Damber JE. Testosterone induces vascular endothelial growth factor synthesis in the ventral prostate in castrated rats. J Urol 1999; 161: 1620-1625
    CrossrefPubMedGoogle Scholar
  • 33 Nolan LA, Levy A. The effects of testosterone and oestrogen on gonadectomised and intact male rat anterior pituitary mitotic and apoptotic activity. J Endocrinol 2006; 188: 387-396
    CrossrefPubMedGoogle Scholar
  • 34 Steffens JP, Coimbra LS, Ramalho-Lucas PD, Rossa Jr C, Spolidorio LC. The effect of supra- and subphysiologic testosterone levels on ligature-induced bone loss in rats – a radiographic and histologic pilot study. J Periodontol 2012; 83: 1432-1439
    CrossrefPubMedGoogle Scholar
  • 35 Gao A, Kantarci A, Herrera BS, Gao H, Van Dyke TE. A critical role for suppressors of cytokine signaling 3 in regulating LPS-induced transcriptional activation of matrix metalloproteinase-13 in osteoblasts. Peer J 2013; 1: e51
    PubMedGoogle Scholar
  • 36 Mazur A. The age-testosterone relationship in black, white, and Mexican-American men, and reasons for ethnic differences. Aging Male 2009; 12: 66-76
    CrossrefPubMedGoogle Scholar
  • 37 Ozcelik O, Haytac MC, Seydaoglu G. The effects of anabolic androgenic steroid abuse on gingival tissues. J Periodontol 2006; 77: 1104-1109
    CrossrefPubMedGoogle Scholar
  • 38 Kamis AB, Ibrahim JB. Effects of testosterone on blood leukocytes in plasmodium berghei-infected mice. Parasitol Res 1989; 75: 611-613
    CrossrefPubMedGoogle Scholar
  • 39 Yao G, Liang J, Han X, Hou Y. In vivo modulation of the circulating lymphocyte subsets and monocytes by androgen. Internat Immunopharmacol 2003; 3: 1853-1860
    PubMedGoogle Scholar
  • 40 Brusca MI, Verdugo F, Amighini C, Albaina O, Moragues MD. Anabolic steroids affect human periodontal health and microbiota. Clin Oral Investig. 2013 DOI: 10.1007/s00784-013-1126-9
    PubMedGoogle Scholar
  • 41 Graves DT, Oates T, Garlet GP. Review of osteoimmunology and the host response in endodontic and periodontal lesions. J Oral Microbiol. 2011 3. DOI: 10.3402/jom.v3i0.5304
    PubMedGoogle Scholar
  • 42 Maggio M, Basaria S, Ble A, Lauretani F, Bandinelli S, Ceda GP, Valenti G, Ling SM, Ferrucci L. Correlation between testosterone and the inflammatory marker soluble interleukin-6 receptor in older men. J Clin Endocrinol Metab 2006; 91: 345-347
    CrossrefPubMedGoogle Scholar
  • 43 Khosla S, Atkinson EJ, Dunstan CR, O´Fallon WM. Effect of estrogen versus testosterone on circulating osteoprotegerin and other cytokine levels in normal elderly men. J Clin Endocrinol Metab 2002; 87: 1550-1554
    CrossrefPubMedGoogle Scholar
  • 44 Maggio M, Blackford A, Taub D, Carducci M, Ble A, Metter EJ, Braga-Basaria M, Dobs A, Basaria S. Circulating inflammatory cytokine expression in men with prostate cancer undergoing androgen deprivation therapy. J Androl 2006; 27: 725-728
    CrossrefPubMedGoogle Scholar
  • 45 Malkin CJ, Pugh PJ, Jones RD, Kapoor D, Channer KS, Jones TH. The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profiles in hypogonadal men. J Clin Endocrinol Metab 2004; 89: 3313-3318
    CrossrefPubMedGoogle Scholar
  • 46 Yialamas MA, Dwyer AA, Hanley E, Lee H, Pitteloud N, Hayes FJ. Acute sex steroid withdrawal reduces insulin sensitivity in healthy men with idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab 2007; 92: 4254-4259
    CrossrefPubMedGoogle Scholar
  • 47 Vaishnav R, Beresford JN, Gallagher JA, Russell RG. Effects of the anabolic steroid stanozolol on cells derived from human bone. Clin Sci (Lond) 1988; 74: 455-460
    PubMedGoogle Scholar
  • 48 Hofbauer LC, Hicok KC, Khosla S. Effects of gonadal and adrenal androgens in a novel androgen-responsive human osteoblastic cell line. J Cell Biochem 1998; 71: 96-108
    CrossrefPubMedGoogle Scholar
  • 49 Oury F, Sumara G, Sumara O, Ferron M, Chang H, Smith CE, Hermo L, Suarez S, Roth BL, Ducy P, Karsenty G. Endocrine regulation of male fertility by the skeleton. Cell 2011; 144: 796-809
    CrossrefPubMedGoogle Scholar
  • 50 Nelson CA, Warren JT, Wang MW, Teitelbaum SL, Fremont DH. RANKL employs distinct binding modes to engage RANK and the osteoprotegerin decoy receptor. Structure 2012; 20: 1971-1982
    CrossrefPubMedGoogle Scholar
  • 51 Herrera BS, Ohira T, Gao L, Omori K, Yang R, Zhu M, Muscara MN, Serhan CN, Van Dyke TE, Gyurko R. An endogenous regulator of inflammation, resolvin E1, modulates osteoclast differentiation and bone resorption. Br J Pharmacol 2008; 155: 1214-1223
    CrossrefPubMedGoogle Scholar
  • 52 Gao L, Faibish D, Fredman G, Herrera BS, Chiang N, Serhan CN, Van Dyke TE, Gyurko R. Resolvin E1 and chemokine-like receptor 1 mediate bone preservation. J Immunol 2013; 190: 689-694
    CrossrefPubMedGoogle Scholar
  • 53 Hasturk H, Kantarci A, Ohira T, Arita M, Ebrahimi N, Chiang N, Petasis NA, Levy BD, Serhan CN, Van Dyke TE. RvE1 protects from local inflammation and osteoclast-mediated bone destruction in periodontitis. FASEB J 2006; 20: 401-403
    PubMedGoogle Scholar
  • 54 Hasturk H, Kantarci A, Goguet-Surmenian E, Blackwood A, Andry C, Serhan CN, Van Dyke TE. Resolvin E1 regulates inflammation at the cellular and tissue level and restores tissue homeostasis in vivo. J Immunol 2007; 179: 7021-7029
    PubMedGoogle Scholar